Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Radiation and Temozolomide in Glioblastoma
NCT02599090Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2008
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sorafenib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2008; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02599090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599090.